| miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia CP Pallasch, M Patz, YJ Park, S Hagist, D Eggle, R Claus, ... Blood, The Journal of the American Society of Hematology 114 (15), 3255-3264, 2009 | 178 | 2009 |
| Overexpression of TOSO in CLL is triggered by B-cell receptor signaling and associated with progressive disease CP Pallasch, A Schulz, N Kutsch, J Schwamb, S Hagist, H Kashkar, ... Blood, The Journal of the American Society of Hematology 112 (10), 4213-4219, 2008 | 77 | 2008 |
| Novel X‐linked inhibitor of apoptosis inhibiting compound as sensitizer for TRAIL‐mediated apoptosis in chronic lymphocytic leukaemia with poor prognosis LP Frenzel, M Patz, CP Pallasch, R Brinker, J Claasen, A Schulz, ... British journal of haematology 152 (2), 191-200, 2011 | 37 | 2011 |
| Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies D Thomalla, L Beckmann, C Grimm, M Oliverio, L Meder, CD Herling, ... Blood, The Journal of the American Society of Hematology 140 (20), 2113-2126, 2022 | 33 | 2022 |
| Erufosine, a novel alkylphosphocholine, induces apoptosis in CLL through a caspase-dependent pathway SK Königs, CP Pallasch, LH Lindner, J Schwamb, A Schulz, R Brinker, ... Leukemia research 34 (8), 1064-1069, 2010 | 32 | 2010 |
| An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities R Flümann, T Rehkämper, P Nieper, P Pfeiffer, A Holzem, S Klein, ... Blood cancer discovery 2 (1), 70-91, 2021 | 28 | 2021 |
| MARCKS affects cell motility and response to BTK inhibitors in CLL L Beckmann, V Berg, C Dickhut, C Sun, O Merkel, J Bloehdorn, ... Blood, The Journal of the American Society of Hematology 138 (7), 544-556, 2021 | 12 | 2021 |
| Loss of TOSO Promotes Richter's Transformation of TCL1A Driven CLL A da Palma Guerreiro, C Dorweiler, L Kintzele, D Baatout, M Huelsemann, ... Blood 128 (22), 354, 2016 | 1 | 2016 |
| Overexpression of Lipases Enables Specific Cytotoxicity by the Lipase Inhibitor Orlistat in Chronic Lymphocytic Leukemia Cells. CP Pallasch, J Schwamb, A Schulz, S Debey, D Kofler, JL Schultze, ... Blood 108 (11), 2800, 2006 | 1 | 2006 |
| A Novel BCL2-Driven Compound Mutant Mouse Model for In Vivo Research on BH3 Mimetics I Halmer, A da Palma Guerreiro, L Beckmann, C Reinhardt, H Kashkar, ... Blood 136, 39, 2020 | | 2020 |
| FcmR Shapes BCR Signaling in IgM-Positive Leukemia A da Palma Guerreiro, C Dorweiler, I Halmer, O Merkel, EM Hartmann, ... Blood, The Journal of the American Society of Hematology 132 (Supplement 1 …, 2018 | | 2018 |
| TOSO-Deficient B Cells Show An Impaired NF-κB and Migration Signaling In Vivo A Schulz, CP Pallasch, M Hallek, LP Frenzel, C Wendtner Blood 118 (21), 1779, 2011 | | 2011 |
| Microenvironment Influences Expression of TOSO–a Novel NF-Kappa B Target Gene In Chronic Lymphocytic Leukemia LP Frenzel, A Schulz, CP Pallasch, R Claus, S Ponader, JA Burger, ... Blood 116 (21), 695, 2010 | | 2010 |
| Novel X-linked inhibitor of apoptosis (XIAP) inhibiting compound as sensitizer for TRAIL-mediated apoptosis in chronic lymphocytic leukemia with poor prognosis LP Frenzel, M Patz, CP Pallasch, R Brinker, J Claasen, A Schulz, ... Blood 116 (21), 1375, 2010 | | 2010 |
| Deregulation of miRNAs by Epigenetic Silencing Disrupts Suppression of the Oncogene PLAG1 in Chronic Lymphocytic Leukemia. CP Pallasch, M Patz, YJ Park, S Hagist, D Eggle, R Claus, ... Blood 114 (22), 3463, 2009 | | 2009 |
| Deregulation of Micrornas Results in Overexpression of Oncogenic Transcription Factors Involved in Pathogenesis of CLL. CP Pallasch, S Hagist, M Patz, A Schulz, S Debey, D Eggle, JL Schultze, ... Blood 112 (11), 2075, 2008 | | 2008 |
